Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes
Nutrition, Metabolism and Cardiovascular Diseases · 2026-09 · 36 (9) · 104728
DOI: 10.1016/j.numecd.2026.104728 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026-09. Verfasst von Mario Crisci und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, AORN dei Colli Monaldi Hospital, Naples, Italy. Hauptthemen laut MEDLINE: Platelet Aggregation, PCSK9 Inhibitors, Antibodies, Monoclonal, Humanized, Serine Proteinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
BACKGROUND AND AIM: The impact of proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors on platelet reactivity in the setting of diabetes mellitus (DM) has not been adequately investigated. METHODS AND RESULTS: Out of 52 outpatients with atherosclerotic cardiovascular disease (ASCVD) with an indication for PCSK9 inhibitor alirocumab, 37 patients (mean age 68.1 ± 5.6 years, 62% males) were included in the study and retrospectively divided into two groups according to the presence of DM (DM+/DM-). A blood sample for platelet function testing was collected at baseline (T0), before initiation of alirocumab, and after 3 months of therapy (T90). Light transmission aggregometry was performed to study platelet aggregation, and results were expressed as percentage of maximum platelet aggregation (MPA). At 90-day follow-up, a significant reduction of total cholesterol and low-density lipoprotein cholesterol levels compared to baseline was observed in both DM+ and DM-groups. At baseline, MPA were comparable between the two groups. At T90, only in the DM + cohort, platelet aggregation induced by adenosine diphosphate (ADP) and arachidonic acid (AA) was significantly reduced compared to baseline (ADP 20 μM: 56.00 ± 28.67% vs 63.16 ± 33.69%, at T90 vs T0 respectively, p = 0.011; AA 1 mM: 28.68 ± 40.10% vs 41.74 ± 46.85%, p = 0.025). No significant change in platelet function from baseline was observed in patients DM- (p > 0.05 for all comparisons). CONCLUSION: The PCSK9 inhibitor alirocumab significantly reduced AA and ADP residual platelet aggregation after 90 days of therapy in patients with ASCVD and diabetes, but not in those without diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, AORN dei Colli Monaldi Hospital, Naples, Italy.
- Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy. Electronic address: federica.ilardi@unina.it.
- Division of Cardiology, Department of Advanced Biomedical Sciences, University Federico II of Naples, Italy.
- University of Campania Luigi Vanvitelli, Naples, Italy.
- Department of Cardiac Surgery and Transplants, AORN dei Colli Monaldi Hospital, Naples, Italy.
- Department of Prevention, UOC SIAN, ASL Napoli 2 Nord, Italy.
Zitieren
APA
Crisci, M., Ilardi, F., Manzo, R., Gragnano, F., Paolillo, R., Giugliano, G., Piro, O., Cigala, E., Monteforte, I., D'Oria, V., Venga, E., Marotta, A., Salvato, A., Calabrò, P., Esposito, G., Di Lorenzo, E., & De Feo, M. (2026). Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 36(9), 104728. https://doi.org/10.1016/j.numecd.2026.104728
Vancouver
Crisci M, Ilardi F, Manzo R, Gragnano F, Paolillo R, Giugliano G, et al. Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(9):104728. doi:10.1016/j.numecd.2026.104728
BibTeX
@article{Crisci2026,
author = {Crisci, Mario and Ilardi, Federica and Manzo, Rachele and Gragnano, Felice and Paolillo, Roberta and Giugliano, Giuseppe and Piro, Orlando and Cigala, Emanuele and Monteforte, Ida and D'Oria, Veronica and Venga, Enzo and Marotta, Alessandra and Salvato, Angela and Calabrò, Paolo and Esposito, Giovanni and Di Lorenzo, Emilio and De Feo, Marisa},
title = {Effect of proprotein convertase subtilisin kexin 9 inhibitors on platelet aggregation in patients with and without diabetes},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2026},
volume = {36},
number = {9},
pages = {104728},
doi = {10.1016/j.numecd.2026.104728}
}
EUVIMED